Investors should consider buying AbbVie over Nvidia due to steady growth potential and dividends.

From Nasdaq: 2024-05-26 08:10:00

Nvidia (NASDAQ: NVDA) has shown strong performance but is trading at a high valuation of nearly 40 times its future profits, making it risky for investors. Looking at other industries, AbbVie (NYSE: ABBV) presents an attractive investment opportunity with steady growth potential despite recent underwhelming numbers.

Although AbbVie’s revenue dipped due to loss of exclusivity of Humira, new drugs like Skyrizi and Rinvoq are performing well. With strategic acquisitions like ImmunoGen and Cerevel Therapeutics, AbbVie aims for robust growth by 2025 and beyond, backed by over $68 billion in free cash flow over the past three years.

With a modest valuation at 15 times estimated future profits and a 3.8% dividend yield, AbbVie offers a more favorable investment outlook compared to Nvidia. Leading to strong long-term gains, investing in AbbVie now can potentially yield higher returns as the company focuses on future growth and opportunities.

Considered a great stock to buy and hold, AbbVie’s potential for growth and dividends make it an appealing choice for investors looking for stability and returns. As AbbVie works towards a return to robust growth, purchasing shares now could lead to significant gains in the future.

Investors may want to consider buying AbbVie shares as it presents a compelling long-term investment opportunity with strong growth potential and steady dividends. AbbVie’s focus on strategic acquisitions and future growth prospects make it an attractive option for investors seeking stable returns and value.



Read more at Nasdaq: Forget Nvidia, Buy This Magnificent Healthcare Stock Instead